Discontinuation report MYLAN-NAPROXEN EC
Report ID | 55130 |
Drug Identification Number | 02243432 |
Brand name | MYLAN-NAPROXEN EC |
Common or Proper name | NAPROXEN |
Company Name | MYLAN PHARMACEUTICALS ULC |
Market Status | CANCELLED POST MARKET |
Active Ingredient(s) | NAPROXEN |
Strength(s) | 375MG |
Dosage form(s) | TABLET (ENTERIC-COATED) |
Route of administration | ORAL |
Packaging size | 100 BT |
ATC code | M01AE |
ATC description | ANTIINFLAMMATORY/ANTIRHEUMATIC PROD.,NON-STEROIDS |
Reason for discontinuation | Business reasons |
Anticipated discontinuation date | 2018-07-10 |
Actual discontinuation date | 2018-07-10 |
Remaining supply date | 2018-07-10 |
Discontinuation status | Discontinued |
Discontinuation decision reversal | No |
Information on remaining supply | |
Company comments | Discontinued in shortage ID 5916. Last lot 8054933 Expires 31-May-19 |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 85 ADVANCE ROAD ETOBICOKE, ONTARIO CANADA M8Z 2S6 |
Company contact information | Mylan Pharmaceuticals ULC, 85 Advance Road, Etobicoke, ON, M8Z 2S6 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v3 | 2018-07-11 | English | Compare |
v2 | 2018-07-10 | French | Compare |
v1 | 2018-07-10 | English | Compare |
Showing 1 to 3 of 3